{
    "clinical_study": {
        "@rank": "68935", 
        "arm_group": [
            {
                "arm_group_label": "Ebastine/Pseudoephedrine", 
                "arm_group_type": "Active Comparator", 
                "description": "administration of ebastine/pseudoephedrine 1cap/day for 1 week."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "administration of placebo pill 1 cap/day for 1week"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine whether ebastine/pseudoephedrine is effective on subacute cough."
        }, 
        "brief_title": "The Effect of Ebastine/Pseudoephedrine on Subacute Cough", 
        "condition": "Cough", 
        "condition_browse": {
            "mesh_term": "Cough"
        }, 
        "detailed_description": {
            "textblock": "1. Visit 0 week\n\n             -  Patients with subacute cough,area randomized to either ebastine/pseudoephedrine or\n                placebo for 1 week.\n\n             -  The cough severity and quality of life were measure with VAS score and\n                cough-specific quality-of-life questionnaire(CQLQ)\n\n        2. Visit 1 week check VAS score and CQLQ\n\n        3. Visit 4 weeks check VAS score and CQLQ"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with subacute cough(3-8 weeks)\n\n          -  age: 20-70 years\n\n        Exclusion Criteria:\n\n          -  Chest X-ray abnormality(+) as a probable cause of cough\n\n          -  other explainable confirmed diagnosis(+) such as acute infectious disease\n\n          -  Severe cough or cough complication which needs other anti-tussive agents.\n\n          -  on ACEI\n\n          -  with more than three hypertensive agents\n\n          -  change of hypertension medication 3 months ago\n\n          -  immunocompromized host\n\n          -  relative or absolute contraindication for ebastine/pseudoephedrine\n\n               1. hypersensitivity to ebastine/pseudoephedrine\n\n               2. glaucoma\n\n               3. moderate to severe hypertensive disease\n\n               4. coronary heart disease\n\n               5. hyperthyroidism\n\n               6. moderate to severe liver disease\n\n               7. benign prostate hyperplasia\n\n               8. psychological problem\n\n               9. Parkinson's disease\n\n              10. on linezolid or supposed to use it."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065440", 
            "org_study_id": "06-2011-65"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ebastine/Pseudoephedrine", 
                "description": "Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.", 
                "intervention_name": "Rhinoebastel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pseudoephedrine", 
                "Ephedrine", 
                "Ebastine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ebastine/Pseudoephedrine", 
            "subacute cough", 
            "upper airway cough syndrome"
        ], 
        "lastchanged_date": "February 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Dongjak-Gu", 
                    "zip": "156-707"
                }, 
                "name": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Ebastine/Pseudoephedrine on Subacute Cough :a Randomized Placebo-controlled Trial", 
        "overall_official": {
            "affiliation": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center", 
            "last_name": "Chang-Hoon Lee, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of VAS score", 
            "safety_issue": "No", 
            "time_frame": "1 week later after administration of ebastine/pseudoephedrine or placebo"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065440"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of VAS score", 
                "safety_issue": "No", 
                "time_frame": "4 weeks later after administration of ebastine/pseudoephedrine or placebo"
            }, 
            {
                "measure": "The proportion of patients with more than 50 percent decrease in VAS score", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Change of CQLQ score", 
                "safety_issue": "No", 
                "time_frame": "1week later after administration of ebastine/pseudoephedrine or placebo"
            }, 
            {
                "measure": "Change of CQLQ score", 
                "safety_issue": "No", 
                "time_frame": "4 weeks later after administration of ebastine/pseudoephedrine or placebo"
            }, 
            {
                "measure": "The adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}